APA (7th ed.) Citation

DK, K., CB, S., W, L., HN, J., CY, L., S, L., . . . BC, C. (2025). Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab. Molecular cancer therapeutics, 24(3), 354. https://doi.org/10.1158/1535-7163.MCT-24-0501

Chicago Style (17th ed.) Citation

DK, Kim, et al. "Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab." Molecular Cancer Therapeutics 24, no. 3 (2025): 354. https://doi.org/10.1158/1535-7163.MCT-24-0501.

MLA (9th ed.) Citation

DK, Kim, et al. "Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab." Molecular Cancer Therapeutics, vol. 24, no. 3, 2025, p. 354, https://doi.org/10.1158/1535-7163.MCT-24-0501.